NCT06341426View on ClinicalTrials.gov

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin

PHASE2RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

February 1, 2028

Study Completion Date

August 1, 2028

Conditions
Major Depressive DisorderDepressionTreatment-Resistant DepressionMood Disorders
Interventions
DRUG

Single Psychedelic Dose Psilocybin

One psychedelic dose (1mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy

DRUG

Two Psychedelic Doses Psilocybin

Two psychedelic doses (25 mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy

Trial Locations (1)

M5T 2S8

RECRUITING

Toronto Western Hospital, Toronto

All Listed Sponsors
collaborator

Centre for Addiction and Mental Health

OTHER

lead

University Health Network, Toronto

OTHER